Drug intelligence / Profile preview

amoxicillin + ampicillin + gentamicin + penicillin

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral, Intravenous, Intramuscular

Overview

This is not a single drug product but a combination of four separate antibiotics (amoxicillin, ampicillin, gentamicin, and penicillin) that may be used in various therapeutic combinations. The World Health Organization recommends combinations such as gentamicin with benzylpenicillin, ampicillin, or amoxicillin as first-line treatments for sepsis in neonates and children. These antibiotics work through different mechanisms to provide broad-spectrum coverage against various bacterial infections.

Targets

Bacterial RibosomePBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on amoxicillin + ampicillin + gentamicin + penicillin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amoxicillin + ampicillin + gentamicin + penicillin.

Explore the full profile